Affordability of medicines from the pharmaceutical system perspective
Comparative analysis of Finland and New Zealand
Myymäläsaatavuus
Listassa arvioitu tuotesaatavuus myymälöittäin, saatavuus voi muuttua nopeasti. Myymälähinta voi poiketa verkkokaupan hinnasta.
Tuotetiedot
-
Näytä kaikki
- Kustantaja Kansaneläkelaitos
- ISBN 9789522840196
- Tuotekoodi 9789522840196
- Alanimike Comparative analysis of Finland and New Zealand
- Kirjoittajat Katri Aaltonen
- Sarja Studies in social security and health
- Kieli englanti
- Thema-luokitus Yhteiskunta ja kulttuuri: yleinen; Sosiaaliapalvelut ja -huolto, kriminologia
- Ilmestymispäivä 01.01.2017
- Vuosi 2017
- Sivumäärä 137
- Asiasanat lääkekorvaukset; lääkkeet; saatavuus; lääkehoito; kustannukset; eriarvoisuus; terveyspalvelut; omavastuu; vertaileva tutkimus; Suomi; Uusi-Seelanti
- Kirjastoluokka 37
- Uusintapainoksen pvm 01.01.2017
- Tuotemuoto Pehmeäkantinen kirja
Voisit pitää myös näistä
Tuotekuvaus
Medicines are among the most common and important health care interventions. Most high income countries have implemented reimbursement systems, to ensure economic access to necessary medicines. This study aimed to examine the features of pharmaceutical systems in Finland and New Zealand, and how they translate into affordability-related outcomes.
The study found that the Finnish system provides a wider choice between reimbursed therapeutic options, and faster availability of new innovative medicines. However, medicines were subject to higher patient payments, which had inequitable effects.
Within the New Zealand system, patient payments are generally low for most health needs, but the choice between therapeutic options is narrower and the availability of new innovative medicines lower. Despite the narrow range, the utilisation of non-reimbursed medicines was rare among older people and did not seem to have a socioeconomic gradient.
The study found that the Finnish system provides a wider choice between reimbursed therapeutic options, and faster availability of new innovative medicines. However, medicines were subject to higher patient payments, which had inequitable effects.
Within the New Zealand system, patient payments are generally low for most health needs, but the choice between therapeutic options is narrower and the availability of new innovative medicines lower. Despite the narrow range, the utilisation of non-reimbursed medicines was rare among older people and did not seem to have a socioeconomic gradient.